Niktimvo, niraparib + bevacizumab class
Chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy, in patients weighing… · Hematology (chronic graft-versus-host disease)
About Niktimvo
Niktimvo (axatilimab-csfr) is manufactured by chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy, in patients weighing at least 40 kg. It is a First-in-class anti-CSF-1R monoclonal antibody (IV infusion) approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Niktimvo
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Niktimvo for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Niktimvo is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Niktimvo in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Niktimvo
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.